Anti-BCMA Therapies Aim To Raise The Bar In Myeloma
ASCO Offers Stage For New Data For CAR-T And ADC Candidates
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
You may also be interested in...
Pulling Back The Curtain On Biopharma Partnering In Cell And Gene Therapies
Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
Moment Of Truth For Belantamab Mafodotin, Trikafta And Turalio At EMA
A number of drug companies are set to learn the fate of their marketing authorization applications in the EU this week.